

Recommended Standards for Vaccine Economic Studies and Presentations to ACIP

**Tracy Lieu, MD, MPH
for the ACIP Working Group**

June 2007

ACIP's Charter

- **“Committee deliberations. . . should include consideration of population-based studies such as efficacy, cost-benefit, and risk-benefit analysis”**
- **ACIP is not asked to consider absolute cost or financing**

Recent History

Year	Month	Economic presentation on:
2004	Oct	Meningococcal
2005	Feb	Pertussis – adolescents
	June	Varicella 2 nd dose, hepatitis A
	Oct	Pertussis – adults
2006	Feb	HPV, rotavirus, pertussis – health care workers
	June	HPV, varicella 2 nd dose, zoster
	Oct	Zoster, rabies post-exp prophylaxis

Challenges in Vaccine Economics

- **Studies use decision analysis or computerized models**
- **We make many, many (!) assumptions**
- **Usually there are areas of uncertainty and scant data**
- **Analyses would be easy to bias**

Problems for ACIP

- Hard to know whether studies are high-quality
- Presentations can be hard to understand
- Need standardization of methods and information offered to ACIP
 - e.g., basic projections of costs and benefits

Working Group Process

- **Mark Messonnier, Martin Meltzer, Tracy Lieu**
- **Drafted recommendations, in part based on USPHS standards**
- **Met with ACIP 4 times**
- **Sought input from CDC leaders and CDC's Health Economics Research Group**

Recommendations

- Every economic study should be carefully reviewed by CDC economist(s) before it can be presented to ACIP or its working groups
- Need to submit manuscript and slides at least 8 weeks in advance
- Follow national standards